Please turn JavaScript on
biotechstrategyblog icon

biotechstrategyblog

Follow Biotechstrategyblog's news and updates in a matter of seconds! We will deliver any update via email, phone or you can read them from here on the site on your own news page.

You can even combine different feeds with the feed for Biotechstrategyblog.

Subscribing and unsubscribing is fast, easy and risk free.

The whole service is free of cost.

Biotechstrategyblog: Biotech Strategy Blog Cancer Conferences New Products

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.25 / day

Message History

In the increasingly crowded world of antibody drug conjugates (ADCs), one payload is apparently no longer enough. Developers are now…

Read full story
The basic idea behind a tetravelent bispecific antibody is it has four antigen binding sites, usually two for each of…

Read full story
Johnson & Johnson (J&J) is no stranger to developing cancer drugs. Of late, it has been seeking to build a…

Read full story
In the post bevacizumab/cetuximab/panitumumab era, colorectal cancer (CRC) has spent some long years as the tumour where new drugs go…

Read full story
This  highlight might be one of my favourite presentations from the annual ESMO conference this year, having followed the progress…

Read full story